Anika End Period Cash Flow vs Net Income Analysis

ANIK Stock

USD 17.87 0.04 0.22%

Anika Therapeutics financial indicator trend analysis is way more than just evaluating Anika Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Anika Therapeutics is a good investment. Please check the relationship between Anika Therapeutics End Period Cash Flow and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

End Period Cash Flow vs Net Income

End Period Cash Flow vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Anika Therapeutics End Period Cash Flow account and Net Income. At this time, the significance of the direction appears to have weak relationship.

The correlation between Anika Therapeutics' End Period Cash Flow and Net Income is 0.37. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Net Income in the same time period over historical financial statements of Anika Therapeutics, assuming nothing else is changed. The correlation between historical values of Anika Therapeutics' End Period Cash Flow and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Anika Therapeutics are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of End Period Cash Flow i.e., Anika Therapeutics' End Period Cash Flow and Net Income go up and down completely randomly.

Correlation Coefficient

0.37

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

End Period Cash Flow

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Anika Therapeutics financial statement analysis. It represents the amount of money remaining after all of Anika Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Anika Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' Selling General Administrative is quite stable compared to the past year. Enterprise Value is expected to rise to about 537.5 M this year, although the value of Tax Provision is projected to rise to (3.7 M).

	2021	2022	2023	2024 (projected)
Gross Profit	82.9M	93.6M	103.1M	108.2M
Total Revenue	147.8M	156.2M	166.7M	175.0M

Gross Profit Total Revenue

Anika Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Non Currrent Assets Other	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.79	0.66	0.59	0.98	0.8	-0.6	0.95	0.51	0.77	0.85	0.69	0.6	0.64	0.6	0.62	0.54	0.45	0.58	0.36	0.89	0.27	0.53	0.64	0.41	0.68
Short Long Term Debt Total	0.79		0.44	0.42	0.8	0.68	-0.52	0.69	0.48	0.65	0.59	0.57	0.68	0.73	0.33	0.55	0.42	0.75	0.36	0.43	0.77	0.06	0.41	0.85	0.42	0.81
Other Current Liab	0.66	0.44		0.97	0.53	0.82	-0.01	0.51	0.81	0.22	0.82	0.09	0.71	0.32	0.83	0.92	0.74	0.28	0.95	0.67	0.37	0.59	0.9	0.43	0.27	0.39
Total Current Liabilities	0.59	0.42	0.97		0.45	0.83	0.08	0.4	0.9	0.14	0.76	0.0	0.77	0.31	0.79	0.92	0.77	0.36	0.95	0.72	0.3	0.68	0.9	0.46	0.28	0.38
Total Stockholder Equity	0.98	0.8	0.53	0.45		0.74	-0.72	0.98	0.42	0.85	0.74	0.8	0.56	0.66	0.43	0.53	0.44	0.44	0.42	0.31	0.95	0.14	0.42	0.63	0.49	0.7
Property Plant And Equipment Net	0.8	0.68	0.82	0.83	0.74		-0.32	0.71	0.76	0.52	0.73	0.43	0.89	0.54	0.62	0.89	0.65	0.41	0.77	0.79	0.66	0.54	0.81	0.63	0.53	0.61
Net Debt	-0.6	-0.52	-0.01	0.08	-0.72	-0.32		-0.71	-0.01	-0.96	-0.14	-0.95	-0.18	-0.58	0.1	-0.03	0.19	-0.28	0.12	-0.09	-0.85	0.44	0.15	-0.46	-0.25	-0.63
Retained Earnings	0.95	0.69	0.51	0.4	0.98	0.71	-0.71		0.36	0.83	0.71	0.81	0.46	0.52	0.41	0.5	0.39	0.24	0.39	0.27	0.93	0.15	0.41	0.48	0.51	0.56
Accounts Payable	0.51	0.48	0.81	0.9	0.42	0.76	-0.01	0.36		0.19	0.59	0.08	0.75	0.28	0.54	0.86	0.67	0.44	0.77	0.7	0.33	0.56	0.79	0.48	0.38	0.4
Cash	0.77	0.65	0.22	0.14	0.85	0.52	-0.96	0.83	0.19		0.37	0.94	0.35	0.64	0.14	0.23	0.03	0.36	0.11	0.23	0.93	-0.22	0.08	0.57	0.3	0.69
Non Current Assets Total	0.85	0.59	0.82	0.76	0.74	0.73	-0.14	0.71	0.59	0.37		0.22	0.57	0.44	0.86	0.69	0.82	0.38	0.82	0.28	0.52	0.53	0.71	0.43	0.17	0.46
Cash And Short Term Investments	0.69	0.57	0.09	0.0	0.8	0.43	-0.95	0.81	0.08	0.94	0.22		0.25	0.57	-0.05	0.14	-0.13	0.23	-0.06	0.19	0.93	-0.27	-0.03	0.48	0.48	0.61
Net Receivables	0.6	0.68	0.71	0.77	0.56	0.89	-0.18	0.46	0.75	0.35	0.57	0.25		0.62	0.43	0.82	0.66	0.63	0.65	0.8	0.48	0.44	0.73	0.74	0.49	0.69
Common Stock Shares Outstanding	0.64	0.73	0.32	0.31	0.66	0.54	-0.58	0.52	0.28	0.64	0.44	0.57	0.62		0.25	0.27	0.21	0.82	0.27	0.33	0.67	-0.08	0.12	0.88	0.18	0.98
Non Current Liabilities Total	0.6	0.33	0.83	0.79	0.43	0.62	0.1	0.41	0.54	0.14	0.86	-0.05	0.43	0.25		0.64	0.66	0.22	0.93	0.34	0.24	0.6	0.66	0.28	-0.14	0.25
Inventory	0.62	0.55	0.92	0.92	0.53	0.89	-0.03	0.5	0.86	0.23	0.69	0.14	0.82	0.27	0.64		0.73	0.31	0.84	0.82	0.41	0.6	0.94	0.48	0.47	0.39
Other Current Assets	0.54	0.42	0.74	0.77	0.44	0.65	0.19	0.39	0.67	0.03	0.82	-0.13	0.66	0.21	0.66	0.73		0.35	0.75	0.31	0.18	0.66	0.84	0.28	0.26	0.26
Other Stockholder Equity	0.45	0.75	0.28	0.36	0.44	0.41	-0.28	0.24	0.44	0.36	0.38	0.23	0.63	0.82	0.22	0.31	0.35		0.27	0.3	0.41	0.03	0.2	0.9	0.09	0.86
Total Liab	0.58	0.36	0.95	0.95	0.42	0.77	0.12	0.39	0.77	0.11	0.82	-0.06	0.65	0.27	0.93	0.84	0.75	0.27		0.6	0.24	0.67	0.84	0.36	0.08	0.32
Property Plant And Equipment Gross	0.36	0.43	0.67	0.72	0.31	0.79	-0.09	0.27	0.7	0.23	0.28	0.19	0.8	0.33	0.34	0.82	0.31	0.3	0.6		0.35	0.45	0.7	0.57	0.48	0.42
Total Current Assets	0.89	0.77	0.37	0.3	0.95	0.66	-0.85	0.93	0.33	0.93	0.52	0.93	0.48	0.67	0.24	0.41	0.18	0.41	0.24	0.35		-0.01	0.26	0.66	0.52	0.71
Short Term Debt	0.27	0.06	0.59	0.68	0.14	0.54	0.44	0.15	0.56	-0.22	0.53	-0.27	0.44	-0.08	0.6	0.6	0.66	0.03	0.67	0.45	-0.01		0.71	0.07	0.26	-0.08
Non Currrent Assets Other	0.53	0.41	0.9	0.9	0.42	0.81	0.15	0.41	0.79	0.08	0.71	-0.03	0.73	0.12	0.66	0.94	0.84	0.2	0.84	0.7	0.26	0.71		0.32	0.46	0.21
Common Stock Total Equity	0.64	0.85	0.43	0.46	0.63	0.63	-0.46	0.48	0.48	0.57	0.43	0.48	0.74	0.88	0.28	0.48	0.28	0.9	0.36	0.57	0.66	0.07	0.32		0.3	0.92
Short Term Investments	0.41	0.42	0.27	0.28	0.49	0.53	-0.25	0.51	0.38	0.3	0.17	0.48	0.49	0.18	-0.14	0.47	0.26	0.09	0.08	0.48	0.52	0.26	0.46	0.3		0.25
Common Stock	0.68	0.81	0.39	0.38	0.7	0.61	-0.63	0.56	0.4	0.69	0.46	0.61	0.69	0.98	0.25	0.39	0.26	0.86	0.32	0.42	0.71	-0.08	0.21	0.92	0.25

Click cells to compare fundamentals

Anika Therapeutics Account Relationship Matchups

Anika Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	330.7M	365.6M	347.5M	349.1M	270.6M	148.0M
Other Current Liab	11.3M	26.3M	20.4M	16.0M	17.8M	18.7M
Total Current Liabilities	16.3M	36.9M	29.8M	27.9M	31.1M	32.6M
Total Stockholder Equity	288.4M	272.4M	287.1M	285.6M	212.3M	120.9M
Property Plant And Equipment Net	73.6M	73.2M	68.6M	79.0M	75.0M	78.7M
Net Debt	(136.1M)	(74.9M)	(75.1M)	(55.4M)	(43.8M)	(46.0M)
Retained Earnings	245.4M	221.4M	225.6M	210.7M	128.1M	71.7M
Accounts Payable	3.8M	9.0M	7.6M	9.1M	9.9M	10.4M
Cash	157.5M	95.8M	94.4M	86.3M	72.9M	54.9M
Non Current Assets Total	96.4M	188.2M	179.0M	179.6M	107.3M	55.4M
Cash And Short Term Investments	184.9M	98.3M	94.4M	86.3M	72.9M	62.2M
Net Receivables	23.1M	24.1M	29.8M	34.6M	36.0M	37.8M
Common Stock Shares Outstanding	14.4M	14.2M	14.6M	14.6M	14.7M	12.7M
Liabilities And Stockholders Equity	330.7M	365.6M	347.5M	349.1M	270.6M	148.0M
Non Current Liabilities Total	26.1M	56.3M	30.7M	35.7M	27.3M	15.3M
Inventory	22.0M	46.2M	36.0M	39.8M	46.4M	48.7M
Other Current Assets	1.4M	8.8M	16.6M	17.7M	8.1M	8.5M
Other Stockholder Equity	48.7M	55.4M	67.1M	81.1M	90.0M	54.8M
Total Liab	42.3M	93.2M	60.5M	63.6M	58.4M	61.3M
Property Plant And Equipment Gross	73.6M	73.2M	47.6M	48.3M	122.6M	128.8M
Total Current Assets	235.7M	177.4M	168.5M	169.5M	163.3M	92.6M
Accumulated Other Comprehensive Income	(5.9M)	(4.5M)	(5.7M)	(6.4M)	(5.9M)	(6.2M)
Non Currrent Assets Other	7.5M	15.4M	20.3M	17.2M	18.7M	19.6M
Common Stock Total Equity	147K	142K	143K	144K	167.9K	139.2K
Short Term Investments	70.0M	27.5M	2.5M	34.6M	39.8M	41.8M
Other Assets	(1.4M)	38.0M	20.3M	18.7M	21.5M	22.5M
Property Plant Equipment	50.8M	50.6M	47.6M	48.3M	55.5M	32.3M
Other Liab	4.7M	35.5M	11.4M	6.8M	6.2M	8.1M
Good Will	7.7M	8.4M	7.8M	7.3M	7.6M	8.0M
Intangible Assets	7.6M	91.2M	82.4M	74.6M	4.6M	4.4M
Net Tangible Assets	294.5M	193.7M	216.2M	232.4M	267.3M	227.7M
Retained Earnings Total Equity	245.4M	221.4M	225.6M	210.7M	242.3M	149.3M
Capital Surpluse	48.7M	55.4M	67.1M	81.1M	73.0M	52.5M
Deferred Long Term Liab	4.3M	11.9M	10.2M	6.4M	7.4M	7.2M
Non Current Liabilities Other	357K	23.6M	1.3M	398K	404K	383.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:

How To Invest In Anika

Details

Is Anika Stock a good investment?

Details

What is Anika Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.51)

Earnings Share

(6.64)

Revenue Per Share

11.139

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.04)

The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Anika End Period Cash Flow vs Net Income Analysis

End Period Cash Flow vs Net Income

End Period Cash Flow vs Net Income Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Net Income

Anika Therapeutics fundamental ratios Correlations

Anika Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Anika Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.98	Total Assets
Retained Earnings	+ 0.98	Total Stockholder Equity
Common Stock	+ 0.98	Common Stock Shares Outstanding
Total Current Liabilities	+ 0.97	Other Current Liab
Retained Earnings	+ 0.95	Total Assets
Total Liab	+ 0.95	Other Current Liab

Cash	- 0.96	Net Debt
Cash And Short Term Investments	- 0.95	Net Debt
Total Current Assets	- 0.85	Net Debt
Net Debt	- 0.72	Total Stockholder Equity
Retained Earnings	- 0.71	Net Debt
Common Stock	- 0.63	Net Debt